A Phase 2 interventional study of cemiplimab in Carcinoma, Basal Cell, sponsored by Regeneron Pharmaceuticals. Completed at 71 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 26th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2017, is one of 46 in phase 2, and was the 90th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
University of Rochester · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 58 · Phase 3 7 · Phase 4 5
First in 1977; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 40 across the 139 interventional studies, 80 across the 26 observational. Of the 119 that completed or were terminated, 48 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 171 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 6 studies filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
19 of the studies in Carcinoma, Basal Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
| NCT06623201Nathalie ZeitouniBlue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | 2026-12-01 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT06384924Tiezhi ZhangRaman Spectroscopy and Skin Cancer | 2027-02-13 |
| NCT05294120Memorial Sloan Kettering Cancer CenterA Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of cemiplimab in accordance with protocol dosing regimen
Drug: cemiplimab
Administration of cemiplimab in accordance with protocol dosing regimen
Drug: cemiplimab
Regimen as per protocol
Also known as: REGN2810, Libtayo
Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR)
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 assessed as per ICR assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.
Time frame: Up to 1422 days (approximately 46 months)
Objective Response Rate (ORR) Per Investigator Assessment
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 per Investigator assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.
Time frame: Up to 1422 days (approximately 46 months)
Duration of Response (DOR) as Assessed by ICR
DOR per ICR was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.
Time frame: Up to 48 months
Duration of Response (DOR) Per Investigator Assessment
DOR per investigator assessment was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.
Time frame: Up to 48 months
Complete Response (CR) Rate as Assessed by ICR
CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.
Time frame: Up to 48 months
Complete Response (CR) Rate Per Investigator Assessment
CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.
Time frame: Up to 48 months
Progression Free Survival (PFS) as Assessed by ICR
PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.
Time frame: Up to 60 months
Progression Free Survival (PFS) Per Investigator Assessment
PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.
Time frame: Up to 60 months
Overall Survival (OS)
OS was measured as time from the start of treatment until death due to any cause. Participants who did not die were censored at the last date that participant was documented to be alive. OS was calculated based on Kaplan-Meier estimate.
Time frame: Up to 60 months
Change From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a higher score indicates higher ("better") quality of life/functioning and a positive change from baseline indicates improvement. For the symptom scales/items, a higher score indicates a higher ("worse") level of symptoms/problems, and a negative change from baseline indicates improvement.
Time frame: Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])
Change From Baseline of Patient-reported Outcomes in Skindex-16 Questionnaire
Skindex-16 questionnaire contains 16 questions related to quality of life in cancer participants. It consisted of a short 16-item assessment completed by the participant, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score was an average of items 1 to 4 expressed in a linear scale from 0 to 100, Emotions scale score was an average of items 5 to 11 expressed in a linear scale from 0 to 100 and Functioning scale score was an average of items 12 to 16 expressed in a linear scale from 0 to 100. A negative change from baseline indicates an improvement in the participants condition compared to the baseline.
Time frame: Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as AEs that developed or worsened during the on-treatment period and treatment-related AEs that occur during post-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs.
Time frame: Up to 1422 days (approximately 46 months)
Serum Concentration at Pre-infusion (Ctrough)
Ctrough of cemiplimab reported.
Time frame: At pre-infusion on Cycle 1 Day 22 and Cycle 3 Day 1 (Each cycle of 9 weeks)
Serum Concentration at End of Infusion (Cmax)
Cmax of cemiplimab was reported.
Time frame: At end-of-infusion (within 10 minutes after the end of infusion) on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle of 9 weeks)
Number of Participants With Anti-Drug Antibody (ADA) Status
Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the cemiplimab ADA assay post first dose when baseline results = negative or missing.
Time frame: Cycle 1: Days 1 and 43; Cycles 3 and 5: Day 1 (Each cycle of 9 weeks)
| Milestone | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Started | 54 | 84 |
| Completed treatment | 11 | 28 |
| Completed | 6 | 19 |
| Not completed | 48 | 65 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 4 | 7 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Non compliance with protocol by participant | 1 | 1 |
| Withdrew: Subject decision | 1 | 9 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Progressive disease | 33 | 36 |
| Withdrew: Withdrawal of consent | 2 | 5 |
| Withdrew: Did not re-consent | 1 | 0 |
| Withdrew: Lost insurance coverage | 1 | 0 |
| Withdrew: Related to radiological outcomes | 0 | 1 |
| Withdrew: Unable to come to site for continued visits | 0 | 1 |
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 assessed as per ICR assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.
| Percentage of Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) | 22.2 (12.0 to 35.6) | 32.1 (22.4 to 43.2) |
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 per Investigator assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.
| Percentage of Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Objective Response Rate (ORR) Per Investigator Assessment | 25.9 (15.0 to 39.7) | 36.9 (26.6 to 48.1) |
DOR per ICR was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.
| Months | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Duration of Response (DOR) as Assessed by ICR | NA (9.8 to NA) | NA (15.5 to NA) |
DOR per investigator assessment was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.
| Months | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Duration of Response (DOR) Per Investigator Assessment | NA (9.8 to NA) | 19.6 (16.7 to NA) |
CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.
| Percentage of Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Complete Response (CR) Rate as Assessed by ICR | 3.7 (0.5 to 12.7) | 8.3 (3.4 to 16.4) |
CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.
| Percentage of Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Complete Response (CR) Rate Per Investigator Assessment | 3.7 (0.5 to 12.7) | 8.3 (3.4 to 16.4) |
PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.
| Months | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by ICR | 10.1 (4.2 to 15.9) | 16.5 (8.6 to 21.8) |
PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.
| Months | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Progression Free Survival (PFS) Per Investigator Assessment | 6.6 (4.2 to 8.3) | 18.1 (10.4 to 21.3) |
OS was measured as time from the start of treatment until death due to any cause. Participants who did not die were censored at the last date that participant was documented to be alive. OS was calculated based on Kaplan-Meier estimate.
| Months | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Overall Survival (OS) | 49.9 (28.4 to NA) | NA (NA to NA) |
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a higher score indicates higher ("better") quality of life/functioning and a positive change from baseline indicates improvement. For the symptom scales/items, a higher score indicates a higher ("worse") level of symptoms/problems, and a negative change from baseline indicates improvement.
| Score on a Scale | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Physical Functioning: Change at Cycle 2 Day 1 | -4.88 ± 14.274 | -1.55 ± 12.101 |
| Physical Functioning: Change at Cycle 3 Day 1 | -1.78 ± 13.481 | -0.56 ± 15.947 |
| Physical Functioning: Change at Cycle 4 Day 1 | -6.60 ± 12.828 | -3.79 ± 17.814 |
| Physical Functioning: Change at Cycle 5 Day 1 | 1.08 ± 10.033 | -2.86 ± 17.063 |
| Physical Functioning: Change at Cycle 6 Day 1 | -1.67 ± 9.734 | 0.33 ± 12.073 |
| Physical Functioning: Change at Cycle 7 Day 1 | -0.38 ± 11.142 | -0.20 ± 15.410 |
| Physical Functioning: Change at Cycle 8 Day 1 | -1.33 ± 12.090 | -3.03 ± 13.549 |
| Physical Functioning: Change at Cycle 9 Day 1 | -2.27 ± 8.765 | -5.06 ± 20.444 |
| Role Functioning: Change at Cycle 2 Day 1 | -2.71 ± 27.442 | -3.11 ± 20.264 |
| Role Functioning: Change at Cycle 3 Day 1 | 5.17 ± 27.854 | -4.87 ± 25.297 |
| Role Functioning: Change at Cycle 4 Day 1 | -3.21 ± 25.394 | -6.06 ± 26.326 |
| Role Functioning: Change at Cycle 5 Day 1 | 5.00 ± 22.361 | -5.33 ± 26.393 |
| Role Functioning: Change at Cycle 6 Day 1 | 6.14 ± 21.667 | -3.33 ± 16.963 |
| Role Functioning: Change at Cycle 7 Day 1 | 12.82 ± 24.677 | -7.07 ± 16.682 |
| Role Functioning: Change at Cycle 8 Day 1 | 15.00 ± 25.398 | -4.04 ± 19.557 |
| Role Functioning: Change at Cycle 9 Day 1 | 9.09 ± 22.808 | -9.77 ± 30.052 |
| Emotional Functioning: Change at Cycle 2 Day 1 | 3.17 ± 19.638 | 1.95 ± 20.483 |
| Emotional Functioning: Change at Cycle 3 Day 1 | 1.15 ± 18.730 | 1.56 ± 18.538 |
| Emotional Functioning: Change at Cycle 4 Day 1 | 3.53 ± 22.007 | 1.39 ± 21.277 |
| Emotional Functioning: Change at Cycle 5 Day 1 | 5.83 ± 24.046 | -4.59 ± 19.622 |
| Emotional Functioning: Change at Cycle 6 Day 1 | 7.02 ± 20.650 | 1.04 ± 19.809 |
| Emotional Functioning: Change at Cycle 7 Day 1 | 3.85 ± 18.199 | -4.63 ± 19.576 |
| Emotional Functioning: Change at Cycle 8 Day 1 | 16.67 ± 25.000 | 3.11 ± 19.810 |
| Emotional Functioning: Change at Cycle 9 Day 1 | 5.30 ± 17.189 | 2.11 ± 17.246 |
| Cognitive Functioning: Change at Cycle 2 Day 1 | 0.78 ± 13.586 | -2.48 ± 26.985 |
| Cognitive Functioning: Change at Cycle 3 Day 1 | -1.72 ± 16.871 | -4.17 ± 23.382 |
| Cognitive Functioning: Change at Cycle 4 Day 1 | -0.64 ± 15.261 | -4.94 ± 21.385 |
| Cognitive Functioning: Change at Cycle 5 Day 1 | -4.17 ± 14.178 | -6.46 ± 25.188 |
| Cognitive Functioning: Change at Cycle 6 Day 1 | -0.88 ± 12.998 | -1.25 ± 19.017 |
| Cognitive Functioning: Change at Cycle 7 Day 1 | -2.56 ± 11.479 | -5.56 ± 18.942 |
| Cognitive Functioning: Change at Cycle 8 Day 1 | -6.06 ± 11.237 | 1.52 ± 17.362 |
| Cognitive Functioning: Change at Cycle 9 Day 1 | -10.61 ± 25.025 | -2.30 ± 23.873 |
| Social Functioning: Change at Cycle 2 Day 1 | 0.39 ± 19.412 | 4.50 ± 21.422 |
| Social Functioning: Change at Cycle 3 Day 1 | 3.45 ± 16.891 | 0.78 ± 21.088 |
| Social Functioning: Change at Cycle 4 Day 1 | 3.85 ± 24.179 | 1.85 ± 23.272 |
| Social Functioning: Change at Cycle 5 Day 1 | 3.33 ± 22.685 | 0.34 ± 23.445 |
| Social Functioning: Change at Cycle 6 Day 1 | 10.53 ± 16.860 | 0.00 ± 24.749 |
| Social Functioning: Change at Cycle 7 Day 1 | 12.82 ± 22.724 | 0.00 ± 18.162 |
| Social Functioning: Change at Cycle 8 Day 1 | 10.61 ± 15.407 | 2.02 ± 23.848 |
| Social Functioning: Change at Cycle 9 Day 1 | 9.09 ± 13.670 | -2.30 ± 27.359 |
| Fatigue: Change at Cycle 2 Day 1 | 5.17 ± 22.919 | 6.44 ± 24.542 |
| Fatigue: Change at Cycle 3 Day 1 | 1.92 ± 18.322 | 6.58 ± 24.901 |
| Fatigue: Change at Cycle 4 Day 1 | -2.56 ± 21.154 | 7.58 ± 25.912 |
| Fatigue: Change at Cycle 5 Day 1 | -5.56 ± 24.048 | 9.67 ± 23.404 |
| Fatigue: Change at Cycle 6 Day 1 | -5.85 ± 19.376 | 7.78 ± 17.649 |
| Fatigue: Change at Cycle 7 Day 1 | -1.71 ± 19.692 | 14.14 ± 20.838 |
| Fatigue: Change at Cycle 8 Day 1 | -7.78 ± 24.595 | 9.09 ± 19.534 |
| Fatigue: Change at Cycle 9 Day 1 | -1.01 ± 16.067 | 12.64 ± 20.080 |
| Nausea/Vomiting: Change at Cycle 2 Day 1 | -0.78 ± 8.095 | 0.22 ± 12.703 |
| Nausea/Vomiting: Change at Cycle 3 Day 1 | 0.00 ± 13.363 | -1.79 ± 12.884 |
| Nausea/Vomiting: Change at Cycle 4 Day 1 | 0.00 ± 16.330 | 0.30 ± 13.414 |
| Nausea/Vomiting: Change at Cycle 5 Day 1 | 0.83 ± 10.080 | 1.00 ± 13.640 |
| Nausea/Vomiting: Change at Cycle 6 Day 1 | -0.88 ± 3.824 | 1.67 ± 13.503 |
| Nausea/Vomiting: Change at Cycle 7 Day 1 | -1.28 ± 14.372 | 3.03 ± 13.472 |
| Nausea/Vomiting: Change at Cycle 8 Day 1 | 0.00 ± 0.000 | 0.51 ± 12.832 |
| Nausea/Vomiting: Change at Cycle 9 Day 1 | 0.00 ± 0.000 | -2.30 ± 13.890 |
| Pain: Change at Cycle 2 Day 1 | -2.33 ± 30.338 | -0.22 ± 26.351 |
| Pain: Change at Cycle 3 Day 1 | -9.77 ± 22.056 | -1.54 ± 30.151 |
| Pain: Change at Cycle 4 Day 1 | 0.00 ± 29.439 | -4.85 ± 25.795 |
| Pain: Change at Cycle 5 Day 1 | -4.17 ± 25.291 | -4.00 ± 25.098 |
| Pain: Change at Cycle 6 Day 1 | -14.04 ± 29.535 | -2.92 ± 24.427 |
| Pain: Change at Cycle 7 Day 1 | -21.79 ± 29.174 | -4.04 ± 24.661 |
| Pain: Change at Cycle 8 Day 1 | -13.64 ± 25.624 | -7.58 ± 25.716 |
| Pain: Change at Cycle 9 Day 1 | -19.70 ± 27.707 | -5.17 ± 24.030 |
| Dyspnoea: Change at Cycle 2 Day 1 | 2.38 ± 17.097 | 1.33 ± 24.162 |
| Dyspnoea: Change at Cycle 3 Day 1 | 3.57 ± 16.578 | -0.51 ± 23.930 |
| Dyspnoea: Change at Cycle 4 Day 1 | 0.00 ± 16.667 | 2.42 ± 24.724 |
| Dyspnoea: Change at Cycle 5 Day 1 | 3.51 ± 21.928 | 0.00 ± 28.054 |
| Dyspnoea: Change at Cycle 6 Day 1 | 1.85 ± 13.873 | -1.67 ± 19.900 |
| Dyspnoea: Change at Cycle 7 Day 1 | 2.78 ± 30.011 | 2.02 ± 21.952 |
| Dyspnoea: Change at Cycle 8 Day 1 | 16.67 ± 36.004 | 2.02 ± 21.952 |
| Dyspnoea: Change at Cycle 9 Day 1 | 6.67 ± 26.294 | 2.30 ± 17.663 |
| Insomnia: Change at Cycle 2 Day 1 | -2.33 ± 26.622 | 0.44 ± 24.195 |
| Insomnia: Change at Cycle 3 Day 1 | -6.90 ± 24.200 | -0.51 ± 26.016 |
| Insomnia: Change at Cycle 4 Day 1 | -10.26 ± 29.468 | -1.82 ± 19.687 |
| Insomnia: Change at Cycle 5 Day 1 | -15.00 ± 31.484 | 1.33 ± 30.087 |
| Insomnia: Change at Cycle 6 Day 1 | -17.54 ± 32.142 | -4.17 ± 24.093 |
| Insomnia: Change at Cycle 7 Day 1 | -7.69 ± 41.172 | 1.01 ± 28.241 |
| Insomnia: Change at Cycle 8 Day 1 | -13.33 ± 54.885 | 3.03 ± 25.500 |
| Insomnia: Change at Cycle 9 Day 1 | -6.06 ± 38.925 | 5.75 ± 25.306 |
| Appetite loss: Change at Cycle 2 Day 1 | 4.65 ± 26.807 | -2.25 ± 27.215 |
| Appetite loss: Change at Cycle 3 Day 1 | -2.30 ± 15.252 | -4.30 ± 22.163 |
| Appetite loss: Change at Cycle 4 Day 1 | -1.28 ± 30.523 | -3.09 ± 26.117 |
| Appetite loss: Change at Cycle 5 Day 1 | 3.33 ± 21.357 | -1.36 ± 30.398 |
| Appetite loss: Change at Cycle 6 Day 1 | -1.75 ± 17.476 | -2.56 ± 29.004 |
| Appetite loss: Change at Cycle 7 Day 1 | -5.13 ± 12.518 | -1.01 ± 30.601 |
| Appetite loss: Change at Cycle 8 Day 1 | -3.33 ± 10.541 | -2.08 ± 31.609 |
| Appetite loss: Change at Cycle 9 Day 1 | -3.03 ± 17.979 | 1.19 ± 30.741 |
| Constipation: Change at Cycle 2 Day 1 | 1.55 ± 19.181 | 2.25 ± 21.603 |
| Constipation: Change at Cycle 3 Day 1 | 0.00 ± 21.822 | 1.06 ± 20.712 |
| Constipation: Change at Cycle 4 Day 1 | -2.56 ± 18.674 | 1.23 ± 21.440 |
| Constipation: Change at Cycle 5 Day 1 | 5.00 ± 16.312 | -0.68 ± 22.037 |
| Constipation: Change at Cycle 6 Day 1 | 0.00 ± 15.713 | -1.67 ± 18.413 |
| Constipation: Change at Cycle 7 Day 1 | 5.13 ± 18.490 | 4.04 ± 13.838 |
| Constipation: Change at Cycle 8 Day 1 | 13.33 ± 23.307 | -2.02 ± 16.540 |
| Constipation: Change at Cycle 9 Day 1 | 0.00 ± 14.907 | 1.15 ± 22.683 |
| Diarhoea: Change at Cycle 2 Day 1 | 3.88 ± 14.924 | 0.45 ± 24.360 |
| Diarhoea: Change at Cycle 3 Day 1 | 1.15 ± 14.037 | -1.04 ± 20.547 |
| Diarhoea: Change at Cycle 4 Day 1 | 3.85 ± 23.715 | -1.85 ± 19.870 |
| Diarhoea: Change at Cycle 5 Day 1 | 6.67 ± 20.520 | -0.68 ± 23.064 |
| Diarhoea: Change at Cycle 6 Day 1 | 3.51 ± 18.904 | -1.67 ± 18.413 |
| Diarhoea: Change at Cycle 7 Day 1 | 0.00 ± 13.608 | 1.01 ± 19.516 |
| Diarhoea: Change at Cycle 8 Day 1 | 0.00 ± 14.907 | -1.01 ± 19.516 |
| Diarhoea: Change at Cycle 9 Day 1 | 0.00 ± 14.907 | -2.30 ± 21.696 |
| Financial Problems: Change at Cycle 2 Day 1 | -3.10 ± 17.539 | -3.15 ± 25.385 |
| Financial Problems: Change at Cycle 3 Day 1 | 0.00 ± 18.144 | -4.23 ± 24.313 |
| Financial Problems: Change at Cycle 4 Day 1 | -5.13 ± 22.494 | -4.94 ± 23.710 |
| Financial Problems: Change at Cycle 5 Day 1 | 0.00 ± 18.732 | -6.80 ± 22.546 |
| Financial Problems: Change at Cycle 6 Day 1 | -1.75 ± 23.501 | -5.83 ± 27.099 |
| Financial Problems: Change at Cycle 7 Day 1 | -2.56 ± 21.350 | 1.01 ± 19.516 |
| Financial Problems: Change at Cycle 8 Day 1 | -3.03 ± 17.979 | 1.01 ± 19.516 |
| Financial Problems: Change at Cycle 9 Day 1 | -6.06 ± 20.101 | -2.30 ± 23.454 |
| Global health status/QoL: Change at Cycle 2 Day 1 | -3.68 ± 21.845 | 2.55 ± 15.298 |
| Global health status/QoL: Change at Cycle 3 Day 1 | 3.74 ± 14.362 | -2.55 ± 19.823 |
| Global health status/QoL: Change at Cycle 4 Day 1 | -2.24 ± 14.636 | -0.49 ± 18.136 |
| Global health status/QoL: Change at Cycle 5 Day 1 | 7.50 ± 14.023 | -1.91 ± 21.210 |
| Global health status/QoL: Change at Cycle 6 Day 1 | 10.96 ± 11.802 | 4.17 ± 19.447 |
| Global health status/QoL: Change at Cycle 7 Day 1 | 16.03 ± 22.428 | -3.13 ± 19.715 |
| Global health status/QoL: Change at Cycle 8 Day 1 | 9.09 ± 13.670 | 2.15 ± 21.727 |
| Global health status/QoL: Change at Cycle 9 Day 1 | 8.33 ± 20.412 | -7.14 ± 28.211 |
Skindex-16 questionnaire contains 16 questions related to quality of life in cancer participants. It consisted of a short 16-item assessment completed by the participant, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score was an average of items 1 to 4 expressed in a linear scale from 0 to 100, Emotions scale score was an average of items 5 to 11 expressed in a linear scale from 0 to 100 and Functioning scale score was an average of items 12 to 16 expressed in a linear scale from 0 to 100. A negative change from baseline indicates an improvement in the participants condition compared to the baseline.
| Score on a Scale | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Emotions: Change at Cycle 2 Day 1 | -6.90 ± 24.422 | -8.93 ± 27.767 |
| Emotions: Change at Cycle 3 Day 1 | -7.92 ± 18.033 | -8.60 ± 25.641 |
| Emotions: Change at Cycle 4 Day 1 | -3.97 ± 17.175 | -11.45 ± 24.215 |
| Emotions: Change at Cycle 5 Day 1 | -0.14 ± 12.835 | -10.25 ± 24.646 |
| Emotions: Change at Cycle 6 Day 1 | -9.08 ± 22.824 | -19.73 ± 27.304 |
| Emotions: Change at Cycle 7 Day 1 | 6.55 ± 17.053 | -13.65 ± 27.132 |
| Emotions: Change at Cycle 8 Day 1 | -0.71 ± 8.478 | -13.97 ± 25.001 |
| Emotions: Change at Cycle 9 Day 1 | 5.70 ± 14.711 | -15.08 ± 31.843 |
| Symptoms: Change at Cycle 2 Day 1 | 0.99 ± 18.788 | -1.31 ± 21.607 |
| Symptoms: Change at Cycle 3 Day 1 | 3.85 ± 16.580 | -0.26 ± 24.158 |
| Symptoms: Change at Cycle 4 Day 1 | 5.30 ± 18.464 | -6.62 ± 23.917 |
| Symptoms: Change at Cycle 5 Day 1 | -0.98 ± 15.205 | -4.11 ± 18.062 |
| Symptoms: Change at Cycle 6 Day 1 | -1.56 ± 16.307 | -1.85 ± 21.419 |
| Symptoms: Change at Cycle 7 Day 1 | 4.17 ± 23.233 | 0.69 ± 24.518 |
| Symptoms: Change at Cycle 8 Day 1 | 5.00 ± 17.213 | -2.96 ± 24.395 |
| Symptoms: Change at Cycle 9 Day 1 | 8.33 ± 21.246 | -3.42 ± 24.455 |
| Functioning: Change at Cycle 2 Day 1 | -3.49 ± 19.183 | -4.98 ± 23.650 |
| Functioning: Change at Cycle 3 Day 1 | -5.00 ± 18.166 | -4.76 ± 20.203 |
| Functioning: Change at Cycle 4 Day 1 | -8.18 ± 24.119 | -5.82 ± 23.275 |
| Functioning: Change at Cycle 5 Day 1 | -7.06 ± 20.746 | -3.76 ± 16.369 |
| Functioning: Change at Cycle 6 Day 1 | -12.08 ± 27.022 | -11.14 ± 18.113 |
| Functioning: Change at Cycle 7 Day 1 | -3.89 ± 19.583 | -6.00 ± 15.767 |
| Functioning: Change at Cycle 8 Day 1 | -7.33 ± 23.402 | -7.00 ± 17.926 |
| Functioning: Change at Cycle 9 Day 1 | -9.39 ± 21.072 | -5.60 ± 20.965 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as AEs that developed or worsened during the on-treatment period and treatment-related AEs that occur during post-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs.
| Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Participants with any TEAEs | 51 | 83 |
| Participants with any Serious TEAEs | 16 | 31 |
Ctrough of cemiplimab reported.
| Milligram per Liter (mg/L) | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Cycle 1 Day 22 | 28.3 ± 18.4 | 29.8 ± 12.0 |
| Cycle 3 Day 1 | 60.6 ± 28.2 | 68.6 ± 32.8 |
Cmax of cemiplimab was reported.
| mg/L | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Cycle 1 Day 1 | 103 ± 25.2 | 104 ± 45.5 |
| Cycle 3 Day 1 | 160 ± 52.7 | 192 ± 91.6 |
Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the cemiplimab ADA assay post first dose when baseline results = negative or missing.
| Participants | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Negative ADA | 50 | 74 |
| Pre-Existing ADA | 2 | 2 |
| Treatment-emergent ADA | 0 | 5 |
Collected over From signature of informed consent until 105 days after last dose of study drug (up to 2129 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Metastatic BCC (mBCC) | 22/54 (40.7%) | 18/54 (33.3%) | 50/54 (92.6%) |
| Group 2: Unresectable Locally Advanced BCC (laBCC) | 21/84 (25%) | 33/84 (39.3%) | 76/84 (90.5%) |
| Event | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| Urinary tract infectionInfections and infestations | 1/54 | 4/84 |
| ColitisGastrointestinal disorders | 2/54 | 2/84 |
| Atrial fibrillationCardiac disorders | 2/54 | 0/84 |
| AnaemiaBlood and lymphatic system disorders | 0/54 | 2/84 |
| Acute kidney injuryRenal and urinary disorders | 0/54 | 2/84 |
| Myocardial infarctionCardiac disorders | 1/54 | 2/84 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 2/84 |
| Adrenal insufficiencyEndocrine disorders | 0/54 | 2/84 |
| PneumoniaInfections and infestations | 1/54 | 0/84 |
| InfectionInfections and infestations | 1/54 | 0/84 |
| Event | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) |
|---|---|---|
| FatigueGeneral disorders | 24/54 | 25/84 |
| DiarrhoeaGastrointestinal disorders | 20/54 | 20/84 |
| PruritusSkin and subcutaneous tissue disorders | 8/54 | 20/84 |
| ConstipationGastrointestinal disorders | 12/54 | 5/84 |
| HypertensionVascular disorders | 12/54 | 9/84 |
| AstheniaGeneral disorders | 5/54 | 17/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/54 | 16/84 |
| Decreased appetiteMetabolism and nutrition disorders | 6/54 | 14/84 |
| NauseaGastrointestinal disorders | 6/54 | 13/84 |
| AnaemiaBlood and lymphatic system disorders | 6/54 | 13/84 |
The full analysis set (FAS) included all enrolled participants for each group who passed screening and were deemed to be eligible for this study.
| Age, Continuous(Years) | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) | Total |
|---|---|---|---|
| Mean | 63.8 ± 11.09 | 69.1 ± 12.84 | 67.0 ± 12.42 |
| Sex: Female, Male(Participants) | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) | Total |
|---|---|---|---|
| Female | 16 | 28 | 44 |
| Male | 38 | 56 | 94 |
| Race/Ethnicity, Customized(Participants) | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) | Total |
|---|---|---|---|
| Race : White | 47 | 57 | 104 |
| Race : Not Reported | 1 | 0 | 1 |
| Race : Missing | 6 | 27 | 33 |
| Race/Ethnicity, Customized(Participants) | Group 1: Metastatic BCC (mBCC) | Group 2: Unresectable Locally Advanced BCC (laBCC) | Total |
|---|---|---|---|
| Ethnicity : Not Hispanic or Latino | 46 | 56 | 102 |
| Ethnicity : Hispanic or Latino | 2 | 1 | 3 |
| Ethnicity : Missing | 6 | 27 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in May 2021, 46 months.
Results were first posted in Jul 2022, 1 year 2 months after primary completion.
Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab